Assessing the therapeutic potential of dendritic cell vaccine in glioblastoma: a protocol for systematic review and meta-analysis

This is the authors' abstract. We don't add key points for this paper.

This study seeks to gather evidence-based information on the therapeutic effect of dendritic cell vaccines in treating glioblastoma. This protocol will follow the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guideline for 2020. In this review, we determined four primary central databases as sources of information: PubMed, Embase, Scopus and the Cochrane Central Register of Controlled Trials. Ethical approval for this study was unnecessary, as we already used published studies. Study findings will be published in journals and presented at conferences for broader dissemination. Highlights The most common and dangerous primary malignant brain tumor, glioblastomas (GBM), are still tricky and challenging to treat. Even with multimodal treatment, victims’ median survival is just 15 months. Active immunotherapy called dendritic cell vaccines (DCV) aims to trigger an anticancer immune system reaction. Hundreds of GBM patients have been vaccinated in numerous DCV trials, which have confirmed the vaccine’s viability and safety. This study aims to assess the rationalistic effect of dendritic cell vaccines for treating GBM.